Fig. 2From: Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case reportImmunofluorescence analysis of programmed cell death ligand 1 (PD-L1) and PD-L2 expression. The panels show fluorescence captions of PD-L1 (a, green) and PD-L2 (b, red) positivity of the same sample (c). Nuclei were stained with 4′, 6-diamidino-2-phenylindole (blue)Back to article page